Cargando…
Why cure, why now?
Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293855/ https://www.ncbi.nlm.nih.gov/pubmed/27273887 http://dx.doi.org/10.1136/medethics-2015-103113 |
_version_ | 1782505145008914432 |
---|---|
author | Kuritzkes, Daniel R |
author_facet | Kuritzkes, Daniel R |
author_sort | Kuritzkes, Daniel R |
collection | PubMed |
description | Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators. |
format | Online Article Text |
id | pubmed-5293855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-52938552017-02-27 Why cure, why now? Kuritzkes, Daniel R J Med Ethics Background Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators. BMJ Publishing Group 2017-02 2016-06-07 /pmc/articles/PMC5293855/ /pubmed/27273887 http://dx.doi.org/10.1136/medethics-2015-103113 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Background Kuritzkes, Daniel R Why cure, why now? |
title | Why cure, why now? |
title_full | Why cure, why now? |
title_fullStr | Why cure, why now? |
title_full_unstemmed | Why cure, why now? |
title_short | Why cure, why now? |
title_sort | why cure, why now? |
topic | Background |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293855/ https://www.ncbi.nlm.nih.gov/pubmed/27273887 http://dx.doi.org/10.1136/medethics-2015-103113 |
work_keys_str_mv | AT kuritzkesdanielr whycurewhynow |